Changes in Hormonal Contraceptive Dispensing Trends Among Commercially Insured Kentucky Females During the COVID-19 Pandemic.

IF 2.4 4区医学 Q3 PHARMACOLOGY & PHARMACY

Pharmacoepidemiology and Drug Safety Pub Date : 2025-05-01 DOI:10.1002/pds.70159

Dustin K Miracle, Lindsey R Hammerslag, Svetla Slavova, Feitong Lei, Jeffery Talbert, Daniela C Moga, Patricia R Freeman

{"title":"Changes in Hormonal Contraceptive Dispensing Trends Among Commercially Insured Kentucky Females During the COVID-19 Pandemic.","authors":"Dustin K Miracle, Lindsey R Hammerslag, Svetla Slavova, Feitong Lei, Jeffery Talbert, Daniela C Moga, Patricia R Freeman","doi":"10.1002/pds.70159","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the impact of the COVID-19 national emergency declaration on contraceptive dispensing trends among commercially insured Kentucky females.Methods: Data ranging from 1/7/2019 through 12/27/2020 for female enrollees aged 19-44 with a primary residence in Kentucky were extracted from the Merative Marketscan Commercial Claims and Encounters Database. A segmented regression analysis was used for statistical modeling of an interrupted time series design to describe changes in weekly contraceptive (oral, transdermal, and vaginal) dispensing rates and days' supply following the COVID-19 national emergency.Results: A total of 90 541 enrollees met study inclusion criteria. The estimated weekly contraceptive dispensing rate per 100 reproductive-aged female enrollees was 3.22 (95% confidence interval [CI] 3.16-3.28) at the beginning of the pre-pandemic period. Following the national emergency, an immediate estimated rate increase of 0.11 (95% CI 0.01-0.21; p = 0.030) was seen with no change in trend. At the beginning of the pre-pandemic period, the estimated weekly percentage of days' supply > 28 days was 29.2% (95% CI 28.8-29.6) with an increasing trend of 1.1% every 10 weeks (slope 0.11 [95% CI 0.09-0.12; p < 0.001]). Following the national emergency, an immediate decrease of 1.5% (95% CI -2.2 to -0.8; p < 0.001) was observed, followed by sustainment of the pre-pandemic trend. No differential impacts were seen with regard to age group (19-26 vs. 27-44) or rural-urban classification.Conclusions: Following the COVID-19 national emergency declaration, trends in both contraceptive dispensing and days' supply among commercially insured Kentucky females were relatively stable, suggesting multiple behavioral and policy-related factors potentially overshadowing changes in access.","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 5","pages":"e70159"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70159","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the impact of the COVID-19 national emergency declaration on contraceptive dispensing trends among commercially insured Kentucky females.

Methods: Data ranging from 1/7/2019 through 12/27/2020 for female enrollees aged 19-44 with a primary residence in Kentucky were extracted from the Merative Marketscan Commercial Claims and Encounters Database. A segmented regression analysis was used for statistical modeling of an interrupted time series design to describe changes in weekly contraceptive (oral, transdermal, and vaginal) dispensing rates and days' supply following the COVID-19 national emergency.

Results: A total of 90 541 enrollees met study inclusion criteria. The estimated weekly contraceptive dispensing rate per 100 reproductive-aged female enrollees was 3.22 (95% confidence interval [CI] 3.16-3.28) at the beginning of the pre-pandemic period. Following the national emergency, an immediate estimated rate increase of 0.11 (95% CI 0.01-0.21; p = 0.030) was seen with no change in trend. At the beginning of the pre-pandemic period, the estimated weekly percentage of days' supply > 28 days was 29.2% (95% CI 28.8-29.6) with an increasing trend of 1.1% every 10 weeks (slope 0.11 [95% CI 0.09-0.12; p < 0.001]). Following the national emergency, an immediate decrease of 1.5% (95% CI -2.2 to -0.8; p < 0.001) was observed, followed by sustainment of the pre-pandemic trend. No differential impacts were seen with regard to age group (19-26 vs. 27-44) or rural-urban classification.

Conclusions: Following the COVID-19 national emergency declaration, trends in both contraceptive dispensing and days' supply among commercially insured Kentucky females were relatively stable, suggesting multiple behavioral and policy-related factors potentially overshadowing changes in access.

查看原文本刊更多论文

在COVID-19大流行期间，肯塔基州商业保险女性激素避孕药配药趋势的变化

目的：评估新冠肺炎国家紧急声明对肯塔基州商业参保女性避孕药具配药趋势的影响。方法：从Merative Marketscan商业索赔和遭遇数据库中提取2019年7月1日至2020年12月27日期间主要居住在肯塔基州的19-44岁女性参保人的数据。采用分段回归分析对中断时间序列设计进行统计建模，以描述COVID-19国家紧急情况后每周避孕药（口服、透皮和阴道）配药率和天数供应的变化。结果：共有90541名入组者符合研究纳入标准。在大流行前时期开始时，估计每100名育龄妇女每周避孕药配药率为3.22（95%可信区间[CI] 3.16-3.28）。在国家紧急状态之后，估计立即增加0.11 (95% CI 0.01-0.21；P = 0.030)，趋势无变化。在大流行前时期开始时，估计每周供应天数百分比为29.2%(95%可信区间28.8-29.6)，每10周增加1.1%(斜率0.11[95%可信区间0.09-0.12；p结论：在2019冠状病毒病国家紧急状态宣布后，肯塔基州商业保险女性的避孕药具分发和天数供应趋势相对稳定，表明多种行为和政策相关因素可能掩盖了获取变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacoepidemiology and Drug Safety 医学-药学

CiteScore

4.80

自引率

7.70%

发文量

173

审稿时长

3 months

期刊介绍： The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.